NTHI

NeOnc Technologies Holdings Inc

3.12

Oct 29 • 3:59 PM ET +0.09 (2.97%)

3.00

Aftermarket • 5:23 PM ET -0.12 (-3.85%)

Healthcare Biotechnology USA Micro NASD

Peers: KZIA CNSP MBIO NUVB CLRB MBRX ANIX CRDF NVCR INO

| Held by: VTI VXF IWC BUSM

Scroll to Statements

Index	-
Market Cap	89.87M
Enterprise Value	88.23M
Income	-47.20M
Sales	0.00M
Book/sh	-0.75
Cash/sh	0.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Mar 26, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	45.62
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.14
Current Ratio	0.14
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-2.12
EPS next Y	-1.11
EPS next Q	-0.25
EPS this Y	56.69%
EPS next Y	20.14%
EPS next 5Y	30.10%
EPS past 3/5Y	-176.88% -109.20%
Sales past 3/5Y	25.98% -
EPS Y/Y TTM	18.94%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-93.43%
Sales Q/Q	-
Earnings	Aug 10 BMO
EPS/Sales Surpr.	-397.00% -

Insider Own	90.84%
Insider Trans	0.70%
Inst Own	10.96%
Inst Trans	1.86%
ROA	-1148.42%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	9.60%
SMA50	-10.95%
SMA200	-43.26%
Trades

Shs Outstand	24.85M
Shs Float	2.64M
Short Float	33.21%
Short Ratio	4.26
Short Interest	0.88M
52W High	12.00 -74.00%
52W Low	2.50 24.75%
Volatility	14.31% 9.87%
ATR (14)	0.31
RSI (14)	51.56
Beta	1.00
Rel Volume	0.35
Avg Volume	205.94K
Volume	71,657

Perf Week	5.76%
Perf Month	-8.37%
Perf Quarter	-10.60%
Perf Half Y	-29.41%
Perf YTD	-62.27%
Perf Year	-67.75%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	17.00
Prev Close	3.03
Price	3.12
Change %	2.97%

Consensus

Strong Buy

Avg. Price Target

$17.00

Implied Upside

+444.9%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 24, 2026	Initiated	RRoth Capital	Buy	$20	+541.0%
May 19, 2026	Initiated	AAlliance Global Partners	Buy	$13	+316.7%
May 18, 2026	Initiated	MMaxim Group	Buy	$20	+541.0%
Apr 24, 2026	Initiated	BBTIG Research	Buy	$15	+380.8%

Oct-26-26 09:19AM	NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries (GlobeNewswire) -13.76%
Oct-23-26 01:01PM	NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue (GlobeNewswire) +10.85%
Oct-22-26 09:28AM	NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight (GlobeNewswire)
08:00AM	NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy (GlobeNewswire)
Oct-21-26 10:17AM	NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches (Newsfile)
09:35AM	Loading…
09:35AM	NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward (GlobeNewswire)
08:00AM	NeOnc Technologies and the Department of Health - Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration (GlobeNewswire)
Oct-20-26 09:33AM	Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season (GlobeNewswire)
Oct-16-26 09:27AM	NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus (Newsfile)
08:56AM	NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone (GlobeNewswire)
08:00AM	NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi (GlobeNewswire)
Oct-15-26 08:57AM	UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances (GlobeNewswire)
08:00AM	NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026 (GlobeNewswire)
Oct-14-26 10:18AM	NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development (GlobeNewswire)
08:00AM	NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors (GlobeNewswire)
09:43AM	Loading…
Oct-07-26 09:43AM	NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer (GlobeNewswire) -9.36%
Oct-06-26 09:02AM	NeOnc's FDA Catalyst Run Could Give NTHI a Serious Jolt (GlobeNewswire)
Sep-29-26 08:52AM	NeOnc's Powerful Brain Cancer Pipeline Advances (GlobeNewswire)
Sep-28-26 09:51AM	Powerful NeOnc Brain Cancer Pipeline Advances (GlobeNewswire)
08:00AM	NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 (GlobeNewswire)
Sep-24-26 10:20AM	NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst (GlobeNewswire)
Sep-22-26 02:52PM	NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier (GlobeNewswire)
Sep-21-26 08:00AM	NeOnc Charting New Nasal Route to Treating Brain Cancer (GlobeNewswire)
Sep-17-26 08:54AM	NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates (GlobeNewswire) +14.05%
08:00AM	NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution (GlobeNewswire)
Sep-16-26 08:46AM	NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA (GlobeNewswire) -9.67%
08:00AM	NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results (GlobeNewswire)
Sep-15-26 09:53AM	Investor Determination to Beat Cancer Puts NeOnc's Novel Therapies and Patented Platform in Focus (GlobeNewswire) -12.43%
Sep-14-26 09:07AM	Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test (GlobeNewswire)
Sep-09-26 09:35AM	NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data (GlobeNewswire) -11.06%
08:00AM	Loading…
08:00AM	NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors (GlobeNewswire)
Sep-08-26 08:39AM	NeOnc' Phase 2 Data Could Put Cancer on the Ropes (GlobeNewswire) -19.09%
Aug-28-26 10:07AM	NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger (GlobeNewswire)
Aug-26-26 09:39AM	NeOnc's Clinical Story Is Now the Main Event (GlobeNewswire)
Aug-18-26 10:18AM	NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't (GlobeNewswire) +12.63%
Aug-17-26 01:31PM	NeOnc Technologies Holdings Inc (NTHI) (Q2 2026) Earnings Call Highlights: First Annual Meeting ... (GuruFocus.com) +16.35%
08:45AM	NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results (GlobeNewswire)
Aug-13-26 04:18PM	Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26 (Newsfile) -7.23% +31.46%
02:31PM	The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech (GlobeNewswire)
Aug-12-26 09:39AM	NeOnc Technologies shares jump after positive Phase 2a glioma results (InvestorsHub) -20.46%
09:38AM	Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer (GlobeNewswire)
09:25AM	NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x (Newsfile)
08:00AM	NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma (GlobeNewswire)
Aug-11-26 08:44AM	NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence (Newsfile Corp.) +24.29%
Aug-10-26 10:34AM	NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears (GlobeNewswire)
09:00AM	NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout (GlobeNewswire)
08:30AM	NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma (GlobeNewswire)
Jul-27-26 09:00AM	NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors (GlobeNewswire)
Jul-15-26 09:00AM	NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition (GlobeNewswire)
Jun-24-26 08:45AM	NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum (GlobeNewswire)
Jun-23-26 09:00AM	NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone (GlobeNewswire)
Jun-22-26 08:45AM	WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy (Newsfile)
Jun-16-26 01:49PM	Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND (GlobeNewswire) +14.86%
09:00AM	NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development (GlobeNewswire)
Jun-15-26 08:35AM	WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates (Newsfile) -5.05%
Jun-09-26 08:45AM	The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade (Newsfile Corp.)
May-29-26 09:05AM	The Next Great AI Revolution May Be Drug Delivery (GlobeNewswire)
May-19-26 10:28AM	NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones (GlobeNewswire)
May-18-26 09:00AM	NeOnc Provides Business Update and Reports Q1 2026 Financial Results (GlobeNewswire)
May-07-26 08:45AM	Biotech's Next Wave May Already be in Motion (GlobeNewswire) +22.22%
May-05-26 09:00AM	NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts (GlobeNewswire) +20.53%
Apr-14-26 09:00AM	NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results (GlobeNewswire)
Apr-01-26 09:00AM	NeOnc Provides Business Update and Reports Q4 2025 Financial Results (GlobeNewswire) -13.12%
Mar-13-26 09:00AM	NeOnc Technologies Appoints David Choi as Chief Accounting Officer (GlobeNewswire)
Mar-12-26 08:52AM	Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) (Newsfile)
Mar-04-26 08:00AM	NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET (GlobeNewswire)
Feb-27-26 09:00AM	NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity (GlobeNewswire)
Jan-30-26 09:00AM	NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management (GlobeNewswire) +5.94%
Jan-09-26 07:32PM	Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) (Newsfile)
Dec-15-25 09:00AM	NeOnc Technologies Reports Updated Clinical Results (GlobeNewswire)
Dec-01-25 09:00AM	NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors (GlobeNewswire)
Nov-14-25 04:01PM	NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update (GlobeNewswire) -12.33%
Nov-13-25 09:00AM	NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High-Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026) (GlobeNewswire) -24.09%
Nov-12-25 08:00AM	NeOnc Technologies Reports Updated Clinical Results (GlobeNewswire)
Nov-07-25 09:00AM	NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program (GlobeNewswire)
Nov-04-25 09:00AM	NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth (GlobeNewswire)
Oct-28-25 09:00AM	His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment (GlobeNewswire) +6.92%
Oct-09-25 09:00AM	NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors (GlobeNewswire)
Oct-06-25 09:00AM	NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals (GlobeNewswire)
Oct-02-25 09:00AM	NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board (GlobeNewswire) +15.40%
Oct-01-25 09:00AM	NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board (GlobeNewswire) +8.70%
Sep-29-25 09:00AM	NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board (GlobeNewswire) -11.39%
Sep-22-25 09:00AM	NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on "Health Uncensored with Dr. Drew" on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT (GlobeNewswire)
Sep-10-25 09:00AM	NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 - A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer (GlobeNewswire) +17.10%
Aug-25-25 09:00AM	NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board (GlobeNewswire)
Aug-19-25 09:00AM	NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update (GlobeNewswire)
Aug-11-25 09:00AM	NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation (GlobeNewswire) +6.68%
Aug-07-25 09:00AM	NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia (GlobeNewswire)
Aug-04-25 09:00AM	NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer (GlobeNewswire)
Jul-30-25 09:00AM	NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors (GlobeNewswire)
Jul-29-25 09:00AM	NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment (GlobeNewswire) -7.76%
Jul-28-25 09:00AM	NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference (GlobeNewswire) +6.08%
Jul-23-25 10:53AM	CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc. (GlobeNewswire)
09:00AM	NeOnc Technologies' Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks - Today at 11:00 a.m. ET (GlobeNewswire)
Jul-22-25 09:00AM	NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment (GlobeNewswire)
Jul-10-25 09:00AM	NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment (GlobeNewswire) -18.05%
Jul-09-25 09:00AM	NeOnc Technologies Holdings, Inc. Joins Russell Microcap Index (GlobeNewswire)
Jul-08-25 09:00AM	NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform (GlobeNewswire)
Jun-06-25 09:00AM	NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs (GlobeNewswire)
Apr-15-25 08:05AM	NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heshmatpour Amir F	CEO, President	Sep 15 '26	Buy	3.30	35,000	115,395	3,183,000	Sep 15 08:47 PM
Heshmatpour Amir F	CEO, President	Sep 14 '26	Buy	3.96	15,000	59,400	3,148,000	Sep 15 08:47 PM
CHEN THOMAS C	CEO	Sep 11 '26	Buy	3.60	5,556	20,002	19,261	Sep 15 08:45 PM
CHEN THOMAS C	CEO	Sep 14 '26	Buy	3.81	5,242	19,998	24,503	Sep 15 08:45 PM
GARNETT KEITHLY	CFO	Sep 14 '26	Buy	3.89	257	1,001	242,357	Sep 15 08:44 PM
KEITHLY GARNETT	Officer	Sep 15 '26	Proposed Sale	3.78	5,000	18,900		Sep 15 04:43 PM
Heshmatpour Amir F	CEO, President	Sep 11 '26	Buy	3.67	37,000	135,620	3,133,000	Sep 14 06:00 AM
CHEN THOMAS C	CEO	Aug 18 '26	Buy	5.49	12,757	69,998	13,705	Aug 20 09:15 PM
CHEN THOMAS C	CEO	Aug 14 '26	Buy	3.85	33,787	130,002	581,059	Aug 18 04:13 PM
CHEN THOMAS C	CEO	Aug 17 '26	Buy	4.04	2,472	9,998	583,531	Aug 18 04:13 PM
Heshmatpour Amir F	CEO, President	Aug 18 '26	Buy	5.54	9,000	49,860	3,096,000	Aug 18 02:30 PM
Heshmatpour Amir F	CEO, President	Aug 14 '26	Buy	3.79	12,000	45,460	3,084,000	Aug 17 06:49 PM
Heshmatpour Amir F	CEO, President	Aug 17 '26	Buy	4.37	3,000	13,120	3,087,000	Aug 17 06:49 PM
Heshmatpour Amir F	President	May 01 '26	Buy	4.16	10,000	41,592	3,072,000	May 04 02:08 PM
Heshmatpour Amir F	President	Apr 28 '26	Buy	4.52	10,000	45,180	3,062,000	Apr 28 06:00 PM
Neman-Ebrahim Yousha	Chief Clinical Officer	Apr 23 '26	Buy	4.88	500	2,440	134,760	Apr 24 06:10 PM
Heshmatpour Amir F	President	Apr 23 '26	Buy	4.90	10,000	49,000	3,052,000	Apr 23 09:34 PM
SUH, DAVID JR.	Chief Accounting Officer	Apr 09 '26	Buy	5.00	200	1,000	111,866	Apr 13 06:15 PM
Heshmatpour Amir F	President	Apr 10 '26	Buy	4.89	10,000	48,950	3,042,000	Apr 10 03:29 PM
Heshmatpour Amir F	President	Apr 08 '26	Buy	5.61	10,000	56,050	3,027,000	Apr 09 02:43 PM
Heshmatpour Amir F	President	Apr 09 '26	Buy	5.19	5,000	25,950	3,032,000	Apr 09 02:43 PM
Heshmatpour Amir F	President	Apr 02 '26	Buy	6.09	20,000	121,798	3,012,000	Apr 06 08:55 PM
Heshmatpour Amir F	President	Apr 06 '26	Buy	6.32	5,000	31,600	3,017,000	Apr 06 08:55 PM
Heshmatpour Amir F	President	Nov 21 '25	Buy	6.07	24,000	145,600	2,986,000	Nov 24 09:10 PM
Heshmatpour Amir F	President	Nov 24 '25	Buy	6.51	6,000	39,060	2,992,000	Nov 24 09:10 PM
Neman-Ebrahim Yousha	Chief Clinical Officer	Nov 20 '25	Buy	6.69	1,100	7,359	134,260	Nov 24 05:46 PM

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.

PresidentMr. Amir Farrokh Heshmatpour

Ph.D.Dr. Thomas C. Chen M.D.

Chief Financial OfficerMr. Keithly A. Garnett

Chief Clinical OfficerDr. Josh Neman-Ebrahim Ph.D.

Chief Accounting OfficerMr. David Choi Jr.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTHI

NeOnc Technologies Holdings Inc

Upgrade your Finviz experience